← boardnext 2027-01next 2027-12next 2027-12-31
NUVL
Nuvalent Inc.distress 1/10 · well-funded / low risk$123.960%today0% from 52w high
Lead: Locally Advanced Solid Tumor
Revenue
pre-revenue
Liquidity
$1287M
Runway
4.1 yrs
Shares 1y
—
Price & events
+10.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
+0.4%
1M
+15.7%
3M
+13.7%
6M
+50.3%
1Y
+57.0%
2Y
—
5Y
+561.1%
All
Overview
- Volume
- 0
- 52 Week Range
- $72.16 – $124
- Float Shares
- 49.11M
- Short %
- 6.17%
- % Held by Insiders
- 2.78%
- % Held by Institutions
- 113.30%
- Beta
- 1.14
Pipeline stages · 3 programs
NVL-330
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Neladalkib (NVL-655), Alectinib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Zidesamtinib (NVL-520)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 4 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-01 Estimated 50% readout ~2027-01-31 | Phase 1 | NVL-330 | Locally Advanced Solid Tumor, Metastatic Solid Tumor | — | recruiting |
| 2027-12 Estimated 50% readout ~2028-01-15 | Phase 1/2 | Neladalkib (NVL-655), Midazolam, Repaglinidebreakthroughorphan | Locally Advanced Solid Tumor, Metastatic Solid Tumor | — | recruiting |
| 2027-12-31 Estimated 50% readout ~2028-02-14 | Phase 1/2 | Zidesamtinib (NVL-520)breakthroughorphan | Locally Advanced Solid Tumor, Metastatic Solid Tumor | — | recruiting |
| 2029-12 Estimated 50% readout ~2030-02-14 | Phase 3 | Neladalkib (NVL-655), Alectinibbreakthroughorphan | Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive | — | recruiting |
Catalyst news & presentations · 18
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-06-09partnershipNuvalent entered into a definitive merger agreement to be acquired by GSK for $124 per share in cash.SEC 8-K
- April 7, 2026regulatory submissionFiled (NDA/BLA)neladalkib · NDA submission to FDASEC 8-K
- 2025readoutPhase 2NVL-655 · Report pivotal data from Phase 2 portion of ALKOVE-1 trialSEC 8-K
- early in the second half of 2025trial initiationsecondaryPhase 3neladalkib · Begin enrollment in ALKAZAR Phase 3 trialSEC 8-K
- year-end 2025readoutPhase 1/2neladalkib · Pivotal data from ALKOVE-1 trialSEC 8-K
- 2025readoutPhase 2zidesamtinib · Report pivotal data from Phase 2 portion of ARROS-1 trialSEC 8-K
- 2025-12-16partnershipneladalkib, zidesamtinib · Royalty Pharma acquired a 1.5% preexisting royalty interest in neladalkib and zidesamtinib net sales from an undisclosed third party for up to $315 million.SEC 8-K
- completed on September 22, 2025regulatory submissionFiled (NDA/BLA)zidesamtinib · Completed NDA submissionSEC 8-K
- July 21, 2025trial initiationsecondaryPhase 3neladalkib · Initiation of ALKAZAR Phase 3 trial in TKI-naïve patients vs ALECENSASEC 8-K
- first half of 2025readoutPhase 1/2zidesamtinib · Pivotal data from ARROS-1 trialSEC 8-K
- first half of 2025trial initiationsecondaryPhase 3NVL-655 · Initiate ALKAZAR Phase 3 randomized controlled trial of NVL-655 versus alectinibSEC 8-K
- mid-year 2025regulatory submissionFiled (NDA/BLA)zidesamtinib · NDA submission for TKI pre-treated patientsSEC 8-K
- first half of 2025trial initiationsecondaryPhase 3neladalkib · Initiate ALKAZAR Phase 3 trial for TKI-naïve patientsSEC 8-K
- 2025-06-24fda agreementzidesamtinib · Pre-NDA meeting aligned on submissionSEC 8-K
- 2025-06-24rolling reviewzidesamtinib · FDA accepted NDA into RTOR pilotSEC 8-K
- Tuesday, January 14th at 9:00 a.m. PTconferencedata presentationsecondaryCorporate presentation at 43rd Annual J.P. Morgan Healthcare ConferenceSEC 8-K
- July 22, 2024trial initiationsecondaryPhase 1NVL-330 · First patient dosed in HEROEX-1 Phase 1a/1b trial.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
hold · target $124 (+0% upside) · 9 analysts
- 2026-06-24BernsteinOutperform → Market Perform
- 2026-06-10GuggenheimBuy → Neutral
- 2026-06-10UBSBuy → Neutral
- 2026-06-10BarclaysOverweight → Equal-Weight
- 2026-06-10WedbushOutperform → Neutral
- 2026-06-10Truist SecuritiesBuy → Hold
Competitors — Locally Advanced Solid Tumor
Recent news
- 2026-07-23GSK's $10.6B Nuvalent acquisition delivers first FDA approval ahead of schedule - The Business Journals
- 2026-07-22Bernstein initiates coverage of Nuvalent (NUVL) with outperform recommendation - MSN
- 2026-07-22Medical Device Collaboration and Licensing Deals Report - GlobeNewswire
- 2026-07-22BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasd - Supply Chain Digital
- 2026-07-21BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
- 2026-07-20How Nuvalent Inc. (NUVL) Affects Rotational Strategy Timing - Stock Traders Daily
- 2026-07-17Deerfield group reports 0% ownership in Nuvalent (NUVL) Class A shares - Stock Titan
- 2026-07-17Deerfield holders cash out of Nuvalent (NUVL) at $124 per share - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.